National Collaboration Sample Clauses

National Collaboration. As an integral part of affiliating with TeamCFA, NS will have the right to collaborate with the entire national network of CFAs. Board Training and Recruitment. Assistance with ongoing board training and member recruitment. Board/Staff Gatherings. Periodic sponsored Board Dinners and Staff-Board luncheons for the purpose of furthering the “community” culture of the TeamCFA network. EXHIBIT B ACADEMIC REQUIREMENTS & EVALUATION RUBRIC (Maximum 100 Points) A points-based program to evaluate the progress of schools in the TeamCFA network Schools in the TeamCFA network should strive toward the highest levels of academic, governance and business practices. The matrix provided below will help to identify the progress member schools are making within the TeamCFA network. It will be used annually as measured criteria for school improvement purposes and to maintain schools in good standing within the TeamCFA network. Scores below a 70 in performance in any of the three required areas of academics, governance or business will require a school improvement plan to be implemented that must be approved by the TeamCFA Committee. Two consecutive annual scores below 70 in any one area may be grounds for termination of this Agreement. For each Required Area: Pass (80-100 points) Concern (70-79 points) Improvement Required (0-69 points) With regard to NS’s academic operations programs, NS agrees to: • Commit to an academic achievement target above a clearly defined local peer group of schools as determined by TeamCFA and to submit to TeamCFA an annual report of academic performance results; 30 Points Standard: NS will provide on annual basis to TeamCFA and its board representatives data on state test scores and any nationally-normed test scores administered by the school. Board and administration will commit to making efforts to grow towards reaching a TeamCFA- determined proficiency target above a local peer group. • Implement the Core Knowledge curriculum for grades kindergarten through eight and use phonics-based reading instruction for grades kindergarten through two and progress towards becoming an official Core Knowledge School; 30 Points Standard: NS will communicate with TeamCFA board representatives so that, on an annual basis, TeamCFA board representatives may complete a report in which they discuss K-2 reading curriculum, with emphasis upon implementation of phonics describe extent of implementation of Core Knowledge curriculum, referring to previous Core Knowledge...
AutoNDA by SimpleDocs
National Collaboration. Coalitions consisting of one or more eligible entities under this section may, to the extent practicable, collaborate with other coalitions consisting of one or more eligible entities under this section for purposes of national co- ordination and collaboration with respect to activities to achieve the preparedness and re- sponse goals described under paragraphs (1), (3), (4), (5), and (6) of section 300hh–1(b) of this title.
National Collaboration. As an integral part of affiliating with TeamCFA, NS will have the right to collaborate with the entire national network of CFAs.
National Collaboration. A VaCHISIP II representative will attend the annual National EHDI conference for the purpose of sharing the latest information and collaborating with other experts in the field of early hearing los on best practices in early hearing detection and surveillance. A final VaCHISIP II report will be completed and published online to share with national EHDI stakeholders. Other Collaboration Efforts. Collaboration with other sources is described elsewhere in this application. Specifically, collaboration with (1) Vital records is via EBC integration (see Part 1, Background, VaCHISIP I); (2) Birth defects registry is via VISITS I and II Birth Defects modules (see Part 1, Background, Integrated Data System and VaCHISIP I, Part 1 G3 OB 5 ); (3) Immunization services is via potential data access and linking (see Part 1, Needs Assessment, Audiologic Assessment and Diagnostic Evaluation, and Part 2 G 1 OB 1 and G 3 OB 1); (4) Bloodspots programs via VISITS I and II Birth Defects modules (diagnosed case data are loaded into VISITS); (5) Part C EI via VISITS II automatic/semi-automatic referrals to the Part C EI database and LC activities (see Part 1, Background, VaCHISIP I, and Part 2 G 2 OB 3).

Related to National Collaboration

  • AREAS OF COLLABORATION The School will collaborate under Xxxx Innovation Mission to establish, operate and support ATL in India within the school premises with financial support from NITI Aayog.

  • PRINCIPLES OF COLLABORATION The parties agree to adopt the following principles when carrying out the Project (Principles):

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development cooperation 1. The Parties recognise that development cooperation is a crucial element of their Partnership and an essential factor in the realisation of the objectives of this Agreement as laid down in Article 1. This cooperation can take financial and non-financial forms.

  • Traditional Medicine Cooperation 1. The aims of Traditional Medicine cooperation will be: (a) to build on existing agreements or arrangements already in place for Traditional Medicine cooperation; and (b) to promote information exchanges on Traditional Medicine between the Parties. 2. In pursuit of the objectives in Article 149 (Objectives), the Parties will encourage and facilitate, as appropriate, the following activities, including, but not limited to: (a) encouraging dialogue on Traditional Medicine policies and promotion of respective Traditional Medicine; (b) raising awareness of active effects of Traditional Medicine; (c) encouraging exchange of experience in conservation and restoration of Traditional Medicine; (d) encouraging exchange of experience on management, research and development for Traditional Medicine; (e) encouraging cooperation in the Traditional Medicine education field, mainly through training programs and means of communication; (f) having a consultation mechanism between the Parties' Traditional Medicine authorities; (g) encouraging cooperation in Traditional Medicine therapeutic services and products manufacturing; and (h) encouraging cooperation in research in the fields of Traditional Medicine in order to contribute in efficacy and safety assessments of natural resources and products used in health care.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

Time is Money Join Law Insider Premium to draft better contracts faster.